Hematologic Neoplasms clinical trials at UC Cancer
1 research study open to new patients
open to eligible people ages 18 years and up
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD013 and establish the maximum tolerated dose (MTD) of MGD013. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of MGD013 will also be assessed.
at UCLA UCSF